Filing Flows › Profound Medical (PROF) › Q2 2026 › vs Q1 2026
Profound Medical (PROF) Q2 2026 vs Q1 2026 (quarter over quarter)
Profound Medical's revenue fell $2.9M (-53%) from $5.3M in Q1 2026 to $2.5M in Q2 2026. The biggest changes: Capital equipment −$2.0M (-70%); Recurring - non-capital −$862K (-35%).
Profound Medical, Q2 2026: revenue $2.5M (+12% year over year), operating margin -445.7%, net loss $9.5M, operating cash flow −$11.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Recurring - non-capital | $1.6M | $2.5M | −$862K | -35% |
| Capital equipment | $871K | $2.9M | −$2.0M | -70% |
| Revenue | $2.5M | $5.3M | −$2.9M | -53% |
| Other income, net | $1.6M | $993K | $588K | +59% |
| Net loss | $9.5M | $7.1M | $2.5M | +35% |
| Costs & expenses | $13.6M | $13.4M | $221K | +2% |
| Operating costs | $13.5M | $13.4M | $191K | +1% |
| Income tax | $55K | $25K | $30K | +120% |
| Cost of revenue | $536K | $1.5M | −$969K | -64% |
| Research & development | $5.7M | $5.3M | $392K | +7% |
| SG&A | $7.4M | $6.6M | $768K | +12% |
| Operating cash sources | $12.3M | $9.7M | $2.6M | +27% |
| Depreciation & amortization | $135K | $100K | $35K | +35% |
| Share-based compensation | $874K | $1.0M | −$174K | -17% |
| Cash used in operations | $11.3M | $8.6M | $2.8M | +32% |
| Net loss absorbed | $9.5M | $7.1M | $2.5M | +35% |
| Working capital & other | $2.8M | $2.7M | $129K | +5% |
Questions
How much did Profound Medical's revenue grow quarter over quarter in Q2 2026?
Profound Medical's revenue fell $2.9M (-53%) from $5.3M in Q1 2026 to $2.5M in Q2 2026.
What drove Profound Medical's revenue change in Q2 2026?
Capital equipment −$2.0M (-70%); Recurring - non-capital −$862K (-35%).